)
)
)
Life Biosciences
Life Bio is a clinical-stage [SR3.1]biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary Partial Epigenetic Reprogramming (PER) platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of serious age-related diseases. Life Bio’s lead program, ER-100, is being developed for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with Phase 1 initiated in the first quarter of 2026 for both indications. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.
What is your next catalyst (value inflection) update?
Phase 1 data readout expected in 4Q26
Year Founded
2016
Lead Product in Development
ER-100, Phase 1 clinical trial for optic neuropathies (Glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy) intiiated in 1Q26
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
three
CEO/Top Company Official
Jerry McLaughlin, CEO
When you expect your next catalyst update?
Phase 1 data readout in 4Q26; additional preclinical pipeline data readouts in 2027
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
